Rly-2608

2 trials 2 recruiting

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

2 Recruiting

0 Completed trials

1 Sponsors

16 Countries

Phase III

Phase II

Phase III: 1 Phase II: 1

Indications tested

Hormone receptor positive HER2 negative breast cancer 1 Vascular malformation 1 PIK3CA-activated mutation 1 PIK3CA related overgrowth spectrum 1 Lymphatic malformation 1

Sponsors using this IMP

Relay Therapeutics Inc. 2

All trials

2 total

A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 Phase III 14 countries Relay Therapeutics Inc.
RLY-2608-201-Ph2 Study of RLY-2608 in PROS and PIK3CA Driven Malformations Recruiting

2024-518895-30-00 Phase II 7 countries Relay Therapeutics Inc.

Showing 1–2 of 2 trials

← All drugs A–Z